KIT gene exon 11 mutations in canine malignant melanoma

Veterinary Journal

Volumn 196, Issue 2, 2013, Pages 226-230

  Chu, Pei Yi ^a   Pan, Siou Li ^b   Liu, Chen Hsuan ^b   Lee, Jihjong ^b   Yeh, Lih Seng ^b   Liao, Albert T ^b  

^a St Martin De Porres Hospital   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Dog; Immunohistochemistry; KIT; Melanoma; Mutation

Indexed keywords

NUCLEOTIDE; ONCOPROTEIN; PROTEIN KIT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DOG DISEASE; EXON; FEMALE; GENE MUTATION; HETEROZYGOTE; IMMUNOHISTOCHEMISTRY; KIT GENE; MALE; MELANOMA; NONHUMAN; NUCLEIC ACID ANALYSIS; PROTEIN EXPRESSION; PROTO ONCOGENE;

ANIMALS; DOG DISEASES; DOGS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; SOFT TISSUE NEOPLASMS;

CANIS FAMILIARIS;

EID: 84878938432     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2012.09.005     Document Type: Article

References (39)

1. Alexis J.B., Martinez A.E., Lutzky J. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Research 2005, 15:283-285.
2. Beadling C., Jacobson-Dunlop E., Hodi F.S., Le C., Warrick A., Patterson J., Town A., Harlow A., Cruz F., Azar S., Rubin B.P., Muller S., West R., Heinrich M.C., Corless C.L. KIT gene mutations and copy number in melanoma subtypes. Clinical Cancer Research 2008, 14:6821-6828.
3. Besmer P. The kit ligand encoded at the murine steel locus: A pleiotropic growth and differentiation factor. Current Opinion in Cell Biology 1991, 3:939-946.
4. Chute D.J., Cousar J.B., Mills S.E. Anorectal malignant melanoma: Morphologic and immunohistochemical features. American Journal of Clinical Pathology 2006, 126:93-100.
5. Corless C.L., Fletcher J.A., Heinrich M.C. Biology of gastrointestinal stromal tumors. Journal of Clinical Oncology 2004, 22:3813-3825.
6. de Silva C.M., Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathology Oncology Research 2003, 9:13-19.
7. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., Sugahara H., Butterfield J.H., Ashman L.K., Kanayama Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. Journal of Clinical Investigation 1993, 92:1736-1744.
8. Gleixner K.V., Rebuzzi L., Mayerhofer M., Gruze A., Hadzijusufovic E., Sonneck K., Vales A., Kneidinger M., Samorapoompichit P., Thaiwong T., Pickl W.F., Yuzbasiyan-Gurkan V., Sillaber C., Willmann M., Valent P. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Experimental Hematology 2007, 35:1510-1521.
9. Goldschmidt, M.H., Dunstan, R.W., Stannard, A.A., von Tscharner, C., Walder, E.J., Yager, J.A., 1998. In: World Health Organization International Histological Classification of Epithelial and Melanocytic Tumors of the Skin of Domestic Animals, vol. 3. Armed Forces Institute of Pathology, City.
10. Handolias D., Hamilton A.L., Salemi R., Tan A., Moodie K., Kerr L., Dobrovic A., McArthur G.A. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. British Journal of Cancer 2010, 102:1219-1223.
11. Hashimoto K., Tsujimura T., Moriyama Y., Yamatodani A., Kimura M., Tohya K., Morimoto M., Kitayama H., Kanakura Y., Kitamura Y. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. American Journal of Pathology 1996, 148:189-200.
12. Heinrich M.C., Blanke C.D., Druker B.J., Corless C.L. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. Journal of Clinical Oncology 2002, 20:1692-1703.
13. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Muhammad Tunio G., Matsuzawa Y., Kanakura Y., Shinomura Y., Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
14. Hodi F.S., Friedlander P., Corless C.L., Heinrich M.C., Mac Rae S., Kruse A., Jagannathan J., Van den Abbeele A.D., Velazquez E.F., Demetri G.D., Fisher D.E. Major response to imatinib mesylate in KIT-mutated melanoma. Journal of Clinical Oncology 2008, 26:2046-2051.
15. Isotani M., Ishida N., Tominaga M., Tamura K., Yagihara H., Ochi S., Kato R., Kobayashi T., Fujita M., Fujino Y., Setoguchi A., Ono K., Washizu T., Bonkobara M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine 2008, 22:985-988.
16. Jones C.L., Grahn R.A., Chien M.B., Lyons L.A., London C.A. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. Journal of Veterinary Diagnostic Investigation 2004, 16:95-100.
17. Kitayama H., Kanakura Y., Furitsu T., Tsujimura T., Oritani K., Ikeda H., Sugahara H., Mitsui H., Kanayama Y., Kitamura Y. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995, 85:790-798.
18. Kobayashi M., Sugisaki O., Ishii N., Yamada O., Ito K., Kuroki S., Sasaki Y., Ono K., Washizu T., Bonkobara M. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. The Veterinary Journal 2012, 193:264-267.
19. Lasota J., Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Seminars in Diagnostic Pathology 2006, 23:91-102.
20. Liao A.T., Chien M.B., Shenoy N., Mendel D.B., McMahon G., Cherrington J.M., London C.A. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002, 100:585-593.
21. London C.A., Galli S.J., Yuuki T., Hu Z.Q., Helfand S.C., Geissler E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Experimental Hematology 1999, 27:689-697.
22. Lux M.L., Rubin B.P., Biase T.L., Chen C.J., Maclure T., Demetri G., Xiao S., Singer S., Fletcher C.D., Fletcher J.A. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. American Journal of Pathology 2000, 156:791-795.
23. Modiano J.F., Ritt M.G., Wojcieszyn J. The molecular basis of canine melanoma: Pathogenesis and trends in diagnosis and therapy. Journal of Veterinary Internal Medicine 1999, 13:163-174.
24. Murakami A., Mori T., Sakai H., Murakami M., Yanai T., Hoshino Y., Maruo K. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas. Veterinary and Comparative Oncology 2011, 9:219-224.
25. Newman S.J., Jankovsky J.M., Rohrbach B.W., Leblanc A.K. C-kit expression in canine mucosal melanomas. Veterinary Pathology. 2012, 49:760-765.
26. North S.M., Banks T.A. Small Animal Oncology: An Introduction 2009, Saunders/Elsevier, New York.
27. Ohashi A., Funasaka Y., Ueda M., Ichihashi M. C-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi. Melanoma Research 1996, 6:25-30.
28. Potti A., Hille R.C., Koch M. Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications. Journal of Carcinogenesis 2003, 2:8.
29. Pryer N.K., Lee L.B., Zadovaskaya R., Yu X., Sukbuntherng J., Cherrington J.M., London C.A. Proof of target for SU11654: Inhibition of KIT phosphorylation in canine mast cell tumors. Clinical Cancer Research 2003, 9:5729-5734.
30. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., Hibbard M.K., Chen C.J., Xiao S., Tuveson D.A., Demetri G.D., Fletcher C.D., Fletcher J.A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Research 2001, 61:8118-8121.
31. Shen S.S., Zhang P.S., Eton O., Prieto V.G. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. Journal of Cutaneous Pathology 2003, 30:539-547.
32. Torres-Cabala C.A., Wang W.L., Trent J., Yang D., Chen S., Galbincea J., Kim K.B., Woodman S., Davies M., Plaza J.A., Nash J.W., Prieto V.G., Lazar A.J., Ivan D. Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Modern Pathology 2009, 22:1446-1456.
33. Webster J.D., Yuzbasiyan-Gurkan V., Kaneene J.B., Miller R., Resau J.H., Kiupel M. The role of c-KIT in tumorigenesis: Evaluation in canine cutaneous mast cell tumors. Neoplasia 2006, 8:104-111.
34. Withrow S.J., Vail D.M. Withrow & MacEwen's Small Animal Clinical Oncology 2007, Saunders Elsevier, New York.
35. Woodman S.E., Davies M.A. Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics. Biochemical Pharmacology 2010, 80:568-574.
36. Woodman S.E., Trent J.C., Stemke-Hale K., Lazar A.J., Pricl S., Pavan G.M., Fermeglia M., Gopal Y.N., Yang D., Podoloff D.A., Ivan D., Kim K.B., Papadopoulos N., Hwu P., Mills G.B., Davies M.A. Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Molecular Cancer Therapeutics 2009, 8:2079-2085.
37. Yamada O., Kobayashi M., Sugisaki O., Ishii N., Ito K., Kuroki S., Sasaki Y., Isotani M., Ono K., Washizu T., Bonkobara M. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation. Veterinary Immunology and Immunopathology 2011, 142:101-106.
38. Zemke D., Yamini B., Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Veterinary Pathology 2002, 39:529-535.
39. Zyrek-Betts J., Micale M., Lineen A., Chaudhuri P.K., Keil S., Xue J., Thomas J.E. Malignant blue nevus with lymph node metastases. Journal of Cutaneous Pathology 2008, 35:651-657.